Quick Answer
Emergent BioSolutions Inc. reported R&D Expense of $70.70 million for fiscal year 2024.
Emergent BioSolutions Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2024 | $70.70M | -36.5% |
| 2023 | $111.40M | -40.8% |
| 2022 | $188.30M | -19.9% |
| 2021 | $235.20M | +0.3% |
| 2020 | $234.50M | +3.7% |
| 2019 | $226.20M | +58.4% |
| 2018 | $142.80M | +46.6% |
| 2017 | $97.40M | -8.9% |
| 2016 | $106.90M | -10.3% |
| 2015 | $119.19M | +13.8% |
| 2014 | $104.72M | -12.7% |
| 2013 | $119.93M | -0.2% |
| 2012 | $120.23M | -3.7% |
| 2011 | $124.83M | +39.8% |
| 2010 | $89.30M | +19.7% |
| 2009 | $74.59M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $13.50M | -2.2% | +8.0% |
| June 30, 2025 | $12.50M | -61.8% | -17.2% |
| March 31, 2025 | $15.10M | +0.0% | +9.4% |
| September 30, 2024 | $13.80M | -9.8% | -57.8% |
| June 30, 2024 | $32.70M | +25.8% | +116.6% |
| March 31, 2024 | $15.10M | -62.9% | -1.3% |
| September 30, 2023 | $15.30M | -63.7% | -41.2% |
| June 30, 2023 | $26.00M | -47.8% | -36.1% |
- Emergent BioSolutions Inc. showed a decrease of -36.5% in R&D Expense compared to the prior fiscal year.
- Over the 2009–2024 period, Emergent BioSolutions Inc.’s r&d expense has declined by 5.2% (from $74.59 million to $70.70 million).
- The most recent figure is from Emergent BioSolutions Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 4, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: